LEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting

Stock News12-09

LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in Orlando, Florida, from December 6 to 9, 2025, its self-developed GPRC5D/CD3 bispecific antibody, LBL-034, designed for treating relapsed/refractory multiple myeloma (RRMM), was featured in the first oral presentation on the opening day.

The Phase I/II clinical study of LBL-034, led by Professor Lu Jin from Peking University People's Hospital and conducted across 17 centers in China, demonstrated promising safety and significant anti-tumor activity in RRMM patients, including those with high-risk refractory subgroups. The results highlight its potential as a best-in-class therapy.

According to Frost & Sullivan data, as of November 2024, LBL-034 ranks second globally in clinical progress for GPRC5D-targeted CD3 T-cell engagers, trailing only Johnson & Johnson, while leading in China. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the FDA for the treatment of multiple myeloma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118584289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118584289","market":"fut","top_or_hot":-1,"title":"LEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in Orlando, Florida, from December 6 to 9, 2025, its self-developed GPRC5D/CD3 bispecific antibody, LBL-034, designed for treating relapsed/refractory multiple myeloma (RRMM), was featured in the first oral presentation on the opening day.</p>\n<p>The Phase I/II clinical study of LBL-034, led by Professor Lu Jin from Peking University People's Hospital and conducted across 17 centers in China, demonstrated promising safety and significant anti-tumor activity in RRMM patients, including those with high-risk refractory subgroups. The results highlight its potential as a best-in-class therapy.</p>\n<p>According to Frost & Sullivan data, as of November 2024, LBL-034 ranks second globally in clinical progress for GPRC5D-targeted CD3 T-cell engagers, trailing only Johnson & Johnson, while leading in China. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the FDA for the treatment of multiple myeloma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 14:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in Orlando, Florida, from December 6 to 9, 2025, its self-developed GPRC5D/CD3 bispecific antibody, LBL-034, designed for treating relapsed/refractory multiple myeloma (RRMM), was featured in the first oral presentation on the opening day.</p>\n<p>The Phase I/II clinical study of LBL-034, led by Professor Lu Jin from Peking University People's Hospital and conducted across 17 centers in China, demonstrated promising safety and significant anti-tumor activity in RRMM patients, including those with high-risk refractory subgroups. The results highlight its potential as a best-in-class therapy.</p>\n<p>According to Frost & Sullivan data, as of November 2024, LBL-034 ranks second globally in clinical progress for GPRC5D-targeted CD3 T-cell engagers, trailing only Johnson & Johnson, while leading in China. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the FDA for the treatment of multiple myeloma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"","article_id":"1118584289","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118584289","pubTimestamp":1765262705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","ASH":"Ashland","BK4109":"特种化学制品","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","09887":"维立志博-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK1161":"生物科技"},"translate_title":"2025年ASH年会上公布LBL-034突破性数据，导致BIOLABS-B(09887)上涨超过3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1,"09887":1},"content_text":"LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in Orlando, Florida, from December 6 to 9, 2025, its self-developed GPRC5D/CD3 bispecific antibody, LBL-034, designed for treating relapsed/refractory multiple myeloma (RRMM), was featured in the first oral presentation on the opening day.\nThe Phase I/II clinical study of LBL-034, led by Professor Lu Jin from Peking University People's Hospital and conducted across 17 centers in China, demonstrated promising safety and significant anti-tumor activity in RRMM patients, including those with high-risk refractory subgroups. The results highlight its potential as a best-in-class therapy.\nAccording to Frost & Sullivan data, as of November 2024, LBL-034 ranks second globally in clinical progress for GPRC5D-targeted CD3 T-cell engagers, trailing only Johnson & Johnson, while leading in China. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the FDA for the treatment of multiple myeloma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118584289","isCrawlerRequest":true}